Health

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation For NTX-001 And Provides Update On The Advancements Of NTX-001 For The Treatment Of Peripheral Nerve Injury Requiring Repair

September 11, 2024

CHESTERBROOK, Pa.–(BUSINESS WIRE)–Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking […]

AmorSui Upgrades Protective Product Line In Effort To Set ‘New Standard’ In Health Care

May 10, 2024

A South Philadelphia apparel company launched during the Covid-19 pandemic has unveiled its improved and enhanced line of personal protective equipment (PPE) for health care workers and others. AmorSui was launched in 2020 by Beau Wangtrakuldee, a scientist and entrepreneur who founded the company after a chemical spill in a lab left her with severe burns. […]

Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing

May 6, 2024

Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing. The funding round is being led by 8VC and DCVC Bio. To date, Samsung Life Science Fund (created by Samsung […]

Philadelphia Sits Among Nation’s Elite Life Sciences Hubs In New Colliers Rankings

April 30, 2024

The Philadelphia region takes fourth place in a new ranking of the country’s top life sciences hubs on the strength of its talent pipeline and recent real estate activity. The analysis conducted by the commercial real estate services firm Colliers International focuses on a region’s ability to support and sustain industry growth using factors such […]

Cagent Vascular Raises $30 Million Series C Financing

February 22, 2024

Funds will be used to accelerate US market adoption and to expand the product portfolio of the first and only Serration Angioplasty Technology Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M. U.S. Venture Partners (USVP), led the round. Participation included new […]

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

December 7, 2023

Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). For the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma. “The […]

SAIL Fusion Announces First Implantations Of Its BowTie™ Sacroiliac Fusion System

October 18, 2023

SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon AO principles, today announced that it has conducted the first implantations of its novel BowTie SI Fusion System. The surgeries began on October 14th and were conducted by Dr. Peter Whang, Associate Professor of Orthopaedics […]

Astarte Medical And Tiny Health Join Forces To Optimize Gut Health For Vulnerable Preterm Infants

September 21, 2023

The new partnership will seek to develop an end-to-end NICU solution to stratify and treat at-risk babies. Astarte Medical, a leading pediatric clinical intelligence company, is forming a joint venture with Tiny Health, makers of gut microbiome tests for babies and expecting parents. The partners have agreed to develop a clinical-facing technology solution to support gut […]

Nobias Therapeutics Announces Acceptance Of Late-Breaking Abstract

September 20, 2023

Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, today announced new results. From a Phase 2 clinical trial of NB-001 (fasoracetam) for the treatment of the neuropsychiatric symptoms associated with 22q11.2 deletion syndrome (“22q11DS”) in children have been selected for a poster presentation at the 52nd Child Neurology Society […]

Advent Therapeutics Awarded $3 Million NIH Grant For Novel Neonatal Lung Therapy

July 20, 2023

Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant. This grant allows the Company to position its novel aerosolized vitamin A formulation […]